Current optimization of combined therapy for chronic obstructive pulmonary disease
Testing the new combined bronchodilator Anoro Ellipta in different clinical trials gives proof to its high clinical efficacy and safety in chronic obstructive pulmonary disease. The drug contains the molecules of a sustained-release selective β2-adrenergic receptor agonist (vilanterol) and a muscari...
Main Author: | |
---|---|
Format: | Article |
Language: | Russian |
Published: |
"Consilium Medicum" Publishing house
2015-12-01
|
Series: | Терапевтический архив |
Subjects: | |
Online Access: | https://ter-arkhiv.ru/0040-3660/article/view/31891 |
id |
doaj-1b675da5b5b84bd7a5136186e198f0c4 |
---|---|
record_format |
Article |
spelling |
doaj-1b675da5b5b84bd7a5136186e198f0c42020-11-25T03:13:36Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422015-12-01871210711028907Current optimization of combined therapy for chronic obstructive pulmonary diseaseE N PopovaTesting the new combined bronchodilator Anoro Ellipta in different clinical trials gives proof to its high clinical efficacy and safety in chronic obstructive pulmonary disease. The drug contains the molecules of a sustained-release selective β2-adrenergic receptor agonist (vilanterol) and a muscarinic cholinergic receptor antagonist (umeclidinium bromide). The bronchodilating mechanisms of umeclidinium bromide are in the competitive inhibition of the binding of acetylcholine with muscarinic acetylcholine receptors of airway smooth muscles whereas in those of vilanterol are in that with the stimulation of intracellular adenylate cyclase. On days 1 and 24 after inhalation of the first dose of vilanterol and umeclidinium bromide, there was a significant increase in the forced expiratory volume in one second as compared to placebo. No clinical effects on QT interval on an electrocardiogram and cardiac rhythm were found. The benefits of an inhalation device (Ellipta) are its innovation design ensuring the effective delivery of an aerosol dose into the airway, convenience, and simplicity.https://ter-arkhiv.ru/0040-3660/article/view/31891chronic obstructive pulmonary diseaseumeclidinium bromidevilanterolanoro ellipta |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
E N Popova |
spellingShingle |
E N Popova Current optimization of combined therapy for chronic obstructive pulmonary disease Терапевтический архив chronic obstructive pulmonary disease umeclidinium bromide vilanterol anoro ellipta |
author_facet |
E N Popova |
author_sort |
E N Popova |
title |
Current optimization of combined therapy for chronic obstructive pulmonary disease |
title_short |
Current optimization of combined therapy for chronic obstructive pulmonary disease |
title_full |
Current optimization of combined therapy for chronic obstructive pulmonary disease |
title_fullStr |
Current optimization of combined therapy for chronic obstructive pulmonary disease |
title_full_unstemmed |
Current optimization of combined therapy for chronic obstructive pulmonary disease |
title_sort |
current optimization of combined therapy for chronic obstructive pulmonary disease |
publisher |
"Consilium Medicum" Publishing house |
series |
Терапевтический архив |
issn |
0040-3660 2309-5342 |
publishDate |
2015-12-01 |
description |
Testing the new combined bronchodilator Anoro Ellipta in different clinical trials gives proof to its high clinical efficacy and safety in chronic obstructive pulmonary disease. The drug contains the molecules of a sustained-release selective β2-adrenergic receptor agonist (vilanterol) and a muscarinic cholinergic receptor antagonist (umeclidinium bromide). The bronchodilating mechanisms of umeclidinium bromide are in the competitive inhibition of the binding of acetylcholine with muscarinic acetylcholine receptors of airway smooth muscles whereas in those of vilanterol are in that with the stimulation of intracellular adenylate cyclase. On days 1 and 24 after inhalation of the first dose of vilanterol and umeclidinium bromide, there was a significant increase in the forced expiratory volume in one second as compared to placebo. No clinical effects on QT interval on an electrocardiogram and cardiac rhythm were found. The benefits of an inhalation device (Ellipta) are its innovation design ensuring the effective delivery of an aerosol dose into the airway, convenience, and simplicity. |
topic |
chronic obstructive pulmonary disease umeclidinium bromide vilanterol anoro ellipta |
url |
https://ter-arkhiv.ru/0040-3660/article/view/31891 |
work_keys_str_mv |
AT enpopova currentoptimizationofcombinedtherapyforchronicobstructivepulmonarydisease |
_version_ |
1724645788028502016 |